CMS Open Payments · Program Year 2024
Terumo Cardiovascular Systems Corporation
Terumo Cardiovascular Systems Corporation reported $22,729.74 across General Payments, Research, and Ownership to 185 physicians and teaching hospitals across 185 transactions.
- $22.7K Below-median payer
- All-tracks total
- 185 Above-median volume
- Transactions
- 185 Above-median reach
- Recipients
- −$18.4K
- General Payments vs PY2023
Terumo Cardiovascular Systems Corporation reported $22,729.74 across all CMS Open Payments tracks (General + Research + Ownership) to 185 physicians and teaching hospitals in Program Year 2024 - ranking #1516 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $22,729.74, averaging $122.86 per recipient.
Terumo Cardiovascular Systems Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer terumo-cardiovascular-systems-corporation Terumo Cardiovascular Systems Corporation
$22.7K · #1516/1,925 · 0.0% industry · PY2024
- TOT $22.7K
- RANK #1516
- SHARE 0.0%
- TXN 185
- RCP 185
- CAT 2
- GEN $22.7K
- ΔGEN −$18.4K
- TOP1 24.9%
- PY 2024
Volume peers
Nearest volume peer: Nippon Shinyaku Co.,Ltd ($22.7K)
Terumo Cardiovascular Systems Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Terumo Cardiovascular Systems Corporation's CMS-reported General Payments decreased by $18.4K (−44.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TERUMO CARDIOVASCULAR SYSTEMS CORPORATIONPY2023: TERUMO CARDIOVASCULAR SYSTEMS CORPORATIONPY2024: Terumo Cardiovascular Systems Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $41,083.53
- PY2024
- $22,729.74
What the Data Shows for Terumo Cardiovascular Systems Corporation
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Terumo Cardiovascular Systems Corporation that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
54 transactions worth $16.4K make "Travel and Lodging" the top general-payment category in the 2-category breakdown below, 72.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Travel and Lodging" leads Terumo Cardiovascular Systems Corporation's 2-category general-payment breakdown at $16.4K, 72.0% of the reported total.
How Terumo Cardiovascular Systems Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $16.4K | 54 | 72.0% |
| Food and Beverage | $6.4K | 131 | 28.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $9,294.53 (40.9%) of $22,729.74 in this company's General Payments records across 122 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Terumo Cardiovascular Systems Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Michael L Wells
$5,667.12 across 1 reported transactions
- 2
Rachel R Phillips
$976.39 across 6 reported transactions
- 3
Alfredo H Altamirano
$917.89 across 4 reported transactions
- 4
Nicholas Testa
$867.91 across 4 reported transactions
- 5
Eric T Simolke
$865.22 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Terumo Cardiovascular Systems Corporation ranks #1516 of 1,925 by total payments (bottom 21% by spend) but is notably more concentrated than that alone would suggest -- #1,114 of 1,838 by HHI (bottom 39% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- SIGN Fracture Care International : $6.8K total payments, HHI 815
- Septodont Inc. : $289.4K total payments, HHI 813
- BioHorizons Implant Systems Inc. : $1.4M total payments, HHI 813
- PTC Therapeutics, Inc. : $464.2K total payments, HHI 811
- Planmeca USA, Inc. : $214.2K total payments, HHI 810
- Elevation Spine, Inc. : $38.6K total payments, HHI 810
- Terumo Cardiovascular Systems Corporation (this company) : $22.7K total payments, HHI 809
- Pierre Fabre Pharmaceuticals, Inc. : $53.6K total payments, HHI 809
- Marinus Pharmaceuticals, Inc. : $279.2K total payments, HHI 807
- 3B Medical, Inc. : $29.3K total payments, HHI 805
- ModernaTX, Inc. : $2.4M total payments, HHI 803
- Community Blood Center : $72.5K total payments, HHI 797
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Terumo Cardiovascular Systems Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Terumo Cardiovascular Systems Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Terumo Cardiovascular Systems Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Innovative Medical Products, Inc.
Carter Bloodcare
NovoSource, LLC
CDC Medical LLC
Reel Surgical, Inc.
Put this to use
Terumo Cardiovascular Systems Corporation ranks #1516 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Terumo Cardiovascular Systems Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.